Less Ads, More Data, More Tools Register for FREE

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

Tue, 18th Aug 2020 20:04

MaxCyte Inc - cell and gene therapies firm - Announces expansion of subsidiary CARMA Cell Therapies' ongoing Phase I intraperitoneal delivery and dose-escalation trial of MCY-M11. Says expansion will involve the inclusion of additional patients and the initiation of two additional clinical sites. The new parallel Phase I cohort with the additional patients will evaluate intraperitoneal delivery of MCY-M11 at escalating doses in additional patients with relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma.

"We are very pleased with the progress of this first-in-human trial to date, and have great hopes that we are moving closer towards bringing a more effective immunotherapeutic option for patients with solid tumors," said MaxCyte's Chief Medical Officer Claudio Ullmann.

Current stock price: 347.00 pence

Year-to-date change: up almost three-fold.

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
11 Jun 2024 11:10

IN BRIEF: MaxCyte CEO Maher Masoud buys 100,000 shares

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud acquired 100,00...

4 Jun 2024 14:27

UK shareholder meetings calendar - next 7 days

22 May 2024 21:51

IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strat...

8 May 2024 12:45

MaxCyte reports strong first quarter

(Sharecast News) - MaxCyte reported total first-quarter revenue of $11.3m in an update on Wednesday, making for a 32% increase compared to the same pe...

8 May 2024 09:46

MaxCyte shares rise amid double-digit revenue increase

(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.